By using website you agree to our use of cookies as described in our cookie policy. Learn More


Saama’s Fluid Analytics for Life Sciences Turns Massive Data into Actionable Insights

Helps organizations provide real world evidence analysis and drug development.

Note: TDWI’s editors carefully choose vendor-issued press releases about new or upgraded products and services. We have edited and/or condensed this release to highlight key features but make no claims as to the accuracy of the vendor's statements.

Saama Technologies, Inc., a big data solutions company, has released Fluid Analytics for Life Sciences industry-specific orchestration stack, bringing its services methodology and technology for rapidly orchestrating and analyzing large volumes of data to the life sciences industry.

Saama’s Fluid Analytics hybrid approach blends technology acceleration with human expertise and industry-specific data assets, enabling better business outcomes with speed and specificity. Global pharmaceutical companies can make better clinical decisions before and after a product is introduced to the market, ultimately bringing safer, more effective products to patients in less time.

“Analytics projects often fail due to lack of context-aware insights and delayed outcomes,” said Sagar Anisingaraju, chief strategy officer at Saama. “Building out the required flexible, real-time architectures requires connecting data, technologies, humans, and business ecosystems to continuously learn with each other. Saama is providing an orchestration stack to analytics and applying it to vertical areas such as life sciences to speed specific business outcomes.”

What an Industry-Specific Orchestration Stack Looks Like

Grounded in broad experience implementing high-value analytics projects for two of the world’s three largest pharmaceutical companies and other leaders including Actelion and Otsuka, Saama created pre-built data frameworks and assets that reduce time-to-value and significantly improve ROI for the most common use cases during the clinical development phase and after drugs enter the market. The new Fluid Analytics for Life Sciences enables pharmaceutical companies to analyze and orchestrate data and insights at previously impossible speeds. Three main benefits are:

  • Enterprisewide data model: Consolidates payer, patient, clinical, internal, and new external data into detailed, aggregated, and derived information across multiple lines of business. Facilitates unified conformance and data governance for key business stakeholders.

  • Advanced analytical data components: Facilitates a business intelligence strategy that enables customers to quickly measure success and improve their performance with performance metrics for specific lines of therapies and therapeutic areas.

  • Predefined data mapping: Templates interface with source systems to mitigate development efforts and accelerate implementation of a robust data warehouse and subject area aggregation.

For more information on Fluid Analytics for Life Sciences, please visit

TDWI Membership

Get immediate access to training discounts, video library, research, and more.

Find the right level of Membership for you.